Skip to main content
. 2012 Sep;13(9):731–744. doi: 10.1631/jzus.B1200057

Table 5.

LN behavior with rituximab therapy

Pathology n e n c n p n f
Class IV 49 19 (39.6%) 18 (37.6%) 12 (22.8%)
Class V 14 4 (28.6%) 5 (35.7%) 5 (35.7%)
Class III 4 1 (20.0%) 1 (20.0%) 2 (40.0%)
Class IV+V 3 0 2 (66.6%) 1 (33.3%)

n e: number enrolled; n c: number of complete remission; n p: number of partial remission; n f: number failing to achieve remission